Treatment of overactive bladder: other drug mechanisms

Andersson, Karl‐Erik

doi:10.1016/s0090-4295(99)00495-1

Cited by 83 publications

(15 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although some beneficial effects have been observed in the treatment of detrusor overactivity with indomethacin or flurbiprofen, side effects related to the inhibition of prostanoids synthesis have limited their clinical use (Andersson, 2000). Our results also showed increased sensitivity to exogenous acetylcholine, but impaired contractile responses to exogenous acetylcholine and KCl in bladders from obstructed rats, in agreement with previous reports (Saito et al, 1996;Turner and Brading, 1997;Lluel et al, 2002).…”

Section: Discussionsupporting

confidence: 91%

Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction

2006

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Altered neurogenic and mechanical responses to acetylcholine, ATP and substance P in detrusor from rat with outlet obstruction

2006

View full text Add to dashboard Cite

“…Second, it suppresses PGF, which reduces the detrusor's contractility, thereby reducing the desire to void [16,17]. Third, it suppresses afferent or efferent nerve pathways to raise the threshold of the sense of urination of the central nervous system [18,19]. Last, it affects the sleep cycle of the brain to induce sufficient sleep [20,21].…”

Section: Discussionmentioning

confidence: 99%

Long-Term Effect of Loxoprofen Sodium on Nocturia in Patients with Benign Prostatic Hyperplasia

et al. 2011

View full text Add to dashboard Cite

PurposeWe evaluated the long-term effects of loxoprofen on nocturia in patients with benign prostatic hyperplasia (BPH).Materials and MethodsBetween January 2006 and December 2008, 40 BPH patients with 2 or more episodes of nocturia received an alpha-blocker, 5-alpha reductase inhibitor, and a single dose of 60 mg of loxoprofen at night before sleep for 12 months (Group I). During the same period, 38 BPH patients selected as the control group received an alpha-blocker and 5-alpha reductase inhibitor (Group II). Patients were reevaluated after 3, 6, and 12 months of treatment by the number of nocturia episodes and side effects.ResultsAfter 3 months of treatment, the number of nocturia episodes decreased significantly compared with baseline in both group I and group II (1.9±0.7, 2.1±0.7, respectively, p<0.05). The degree of decrease in nocturia was significantly different between the groups (-1.5±0.9, -1.1±0.9, respectively, p=0.034). After 6 and 12 months, the number of nocturia episodes decreased significantly compared with baseline in both group I and group II (p<0.05), but the degree of decrease was not significantly different between the groups (p>0.05). After 6 and 12 months of treatment in group I, treatment-emergent adverse events, including 5 cases of gastric discomfort (12.5%), 3 cases of leg edema (7.5%), and 1 case of decreased urine volume (2.5%), occurred in 9 of the 40 (22.5%) patients.ConclusionsLoxoprofen can be an effective treatment for patients with nocturia secondary to BPH in the short term. Long-term use of loxoprofen is not recommended because of the side effects.

show abstract

“…Anticholinergics such as oxybutinin chloride, tolterodine tartrate, and trospium chloride and possibly also solifenacin can be used to treated neurogenic bladder symptoms [23]. As tolterodine is less lipophilic, it may be more suitable for patients with cognitive impairment [24].…”

Section: Autonomic Dysfunctionmentioning

confidence: 99%